Larger studies using the validated PTEN assay are needed to ascertain the combined prognostic effect of loss of PTEN expression and MSI, as well as the frequency of loss of PTEN expression in unselected CRC primaries compared to the subset of patients with tissue available from a metastatic site. This evidence concerns the gene PTEN and colorectal carcinoma.